Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.plabm.2021.e00257
Title: Performance of the Roche/Snibe electrochemiluminescent anti-SARS-COV-2 spike assays compared to the Roche/Abbott IgG nucleocapsid and Abbott IgM spike assays
Authors: Lau, C. S.
Wong, M. S.
Hoo, S. P.
Heng, P. Y.
Phua, S. K.
Aw, T. C. 
Keywords: Evaluation
Nucleocapsid antibody assay
SARS-COV-2
Spike antibody assay
Issue Date: 1-Oct-2021
Publisher: Elsevier B.V.
Citation: Lau, C. S., Wong, M. S., Hoo, S. P., Heng, P. Y., Phua, S. K., Aw, T. C. (2021-10-01). Performance of the Roche/Snibe electrochemiluminescent anti-SARS-COV-2 spike assays compared to the Roche/Abbott IgG nucleocapsid and Abbott IgM spike assays. Practical Laboratory Medicine 27 : e00257. ScholarBank@NUS Repository. https://doi.org/10.1016/j.plabm.2021.e00257
Rights: Attribution-NonCommercial-NoDerivatives 4.0 International
Abstract: Introduction: We evaluated the Roche Elecsys Anti-SARS-CoV-2 and Snibe SARS-CoV-2 S-RBD IgG spike chemiluminescent immunoassays and compared them to existing Roche/Abbott nucleocapsid and Abbott IgM spike assays. Methods: We enrolled 184 SARS-CoV-2 RT-PCR positive samples and 215 controls (172 pre-pandemic, and 43 cross-reactivity) to evaluate the Roche spike antibody (anti-SARS-CoV-2-S) assay. For the Snibe evaluation, we included 119 RT-PCR positive samples and 249 controls (200 pre-pandemice, 49 cross-reactivity). 98 cases had been tested on three spike assays (Roche total antibody, Snibe IgG and Abbott IgM). Results: The Roche anti-SARS-CoV-2-S assay had a CV of 0.5% (0.82U/mL) and 2.3% (8.72U/mL) and was linear from 1.16 to 240U/mL. The Snibe assay was linear from 6.43 to 77.7AU/mL, CV of 5.5% (0.43AU/mL) and 8.8% (0.18AU/mL). The Snibe spike assay was significantly more sensitive than the Abbott IgG assay at 0–6 days POS (35.2% vs 3.6%, mean difference 29.6%, 95% CI 17.5 to 41.8, p < 0.0001). Optimized LORs significantly improved the sensitivity of the Roche spike (48.1%–56.7%) and both nucleocapsid assays (Roche 43.3%–65.5%, Abbott 3.6%–18.5%) in early disease. Conclusion: Although both spike assays showed higher sensitivity than their nucleocapsid counterparts, lower, optimized LORs provided the most significant improvements to sensitivity. © 2021 The Authors
Source Title: Practical Laboratory Medicine
URI: https://scholarbank.nus.edu.sg/handle/10635/231988
ISSN: 2352-5517
DOI: 10.1016/j.plabm.2021.e00257
Rights: Attribution-NonCommercial-NoDerivatives 4.0 International
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1016_j_plabm_2021_e00257.pdf412.64 kBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

1
checked on Nov 21, 2022

Page view(s)

9
checked on Nov 17, 2022

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons